The Research

This retrospective study evaluated 131 patients (ages 6-84) with chronic sinus inflammation who used oxymetazoline nasal decongestant combined with nasal corticosteroids twice daily for 1-23 months (median 4 months). Patients applied oxymetazoline first, remained lying on their back for 5 minutes, then applied the steroid spray. All patients also performed saltwater rinses, with most receiving long-term low-dose antibiotic therapy.

This Phase 2, double-blind, placebo-controlled clinical trial assessed the short-term efficacy and safety of combining mometasone furoate nasal spray (MFNS) with oxymetazoline (OXY) for the treatment of seasonal allergic rhinitis (SAR). Over a 15-day period, 705 adolescent and adult subjects were randomized to receive either MFNS alone, OXY alone, MFNS + OXY (once or three times daily), or placebo. The study measured changes in total nasal symptom score (TNSS) and early congestion relief.

This placebo-controlled trial assessed whether combining mometasone furoate (MFNS) and oxymetazoline (OXY) improves quality of life (QoL) in patients with seasonal allergic rhinitis (SAR). Subjects were randomized to one of several treatment arms: MFNS alone, OXY alone, MFNS + OXY once daily, MFNS + OXY three times daily, or placebo. The primary outcome was improvement in QoL as measured by the Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ).

This randomized, double-blind, placebo-controlled, crossover study investigated whether intranasal fluticasone propionate can reverse oxymetazoline-induced tachyphylaxis (diminished decongestant response) and rebound congestion. Nineteen healthy volunteers were treated with oxymetazoline three times daily for 14 days, followed by fluticasone for an additional 3 days, with respiratory measurements taken at key intervals.

This 60-week, randomized, double-blind clinical trial evaluated whether adding oxymetazoline (a topical decongestant) to intranasal corticosteroids (INS) could provide greater symptom relief in patients with chronic rhinitis compared to INS alone. All participants had persistent nasal congestion despite prior use of INS and cetirizine.

This randomized controlled trial assessed the efficacy of combining oxymetazoline, a topical decongestant, with fluticasone furoate, an intranasal corticosteroid, in treating allergic rhinitis. Participants were assigned to receive either the combination therapy, fluticasone furoate alone, oxymetazoline alone, or a placebo over a four-week period.he primary outcome measured was the total nasal symptom score (TNSS), with secondary outcomes including nasal volume assessed by acoustic rhinometry. Patients were treated once nightly for 4 weeks, with follow-up 2 weeks after treatment to assess symptom relief and safety.

This randomized, placebo-controlled clinical trial assessed whether adding oxymetazoline to intranasal corticosteroid therapy (mometasone furoate nasal spray, or MFNS) would enhance treatment outcomes in patients with nasal polyposis. The study evaluated symptom scores, airflow, mucociliary clearance, and polyp size over a 6-week period with twice-daily use.

This systematic review analyzed published studies on the combined use of intranasal corticosteroids (INCS) and oxymetazoline for treating chronic rhinitis—including both allergic and nonallergic types. The goal was to evaluate the safety and efficacy of this combination, particularly in relation to concerns about oxymetazoline-induced rebound congestion (rhinitis medicamentosa).

This prospective, open-label, single-arm, multicenter, real-world observational study evaluated the safety and effectiveness of a once-daily, fixed-dose nasal spray containing fluticasone furoate (a corticosteroid) and oxymetazoline hydrochloride (a decongestant) in patients diagnosed with allergic rhinitis (AR). A total of 388 patients were enrolled and treated for 28 days.